SimBioSys, Inc.

SimBioSys develops cloud-based AI and spatial biophysics software for precision cancer visualization, diagnosis, and treatment planning. The company's core technology combines artificial intelligence, spatial biophysics, and data science to segment tumors and create interactive 3D digital models from medical imaging (primarily DCE-MRI), addressing tumor heterogeneity beyond traditional 2D pathology. TumorSight Viz is the company's flagship product—FDA-cleared for breast cancer surgical planning and preoperative assessment. It transforms 2D MRI studies into 3D visualizations with volumetric calculations and anatomical measurements to support breast conservation decisions. Additional clinical solutions in development include TumorSight Plan (surgical guidance), TumorSight IQ (treatment response prediction), TumorSight Risk (recurrence risk assessment), TumorSight Marker (biomarker selection), and TumorSight Dose (therapeutic dosing). PhenoScope is a research platform supporting biomarker discovery, optimal dosing, combination therapy analysis, and indication expansion. The company serves breast surgeons, oncologists, academic medical centers, and biopharma researchers. Institutional partnerships include Baylor College of Medicine, NYU Langone Health, Yale Medicine, and NorthShore Health. The technology leverages NVIDIA infrastructure for 3D model generation. While TumorSight Viz holds FDA clearance, most advanced clinical applications remain investigational. SimBioSys positions itself at the intersection of precision medicine, surgical planning, and AI-driven oncology diagnostics.